IL17A and cancer: The study highlighted the fact that the post-operative MIP-3α level may therefore be a useful marker to determine the requirement for adjunctive anti-cancer therapy, and the fact that the MIP-3α/CCR6/IL-17 axis should be investigated further as a potential novel therapeutic target.